title: Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin--a prospective study.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of fesoterodine extended-release (ER) plus tamsulosin in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
  
  
  METHODS
  Men aged ≥50 years, with LUTS, prostate volume ≤60 ml and International Prostate Symptom Score (IPSS) ≥13 were enrolled in this study. 173 consecutive patients were treated initially with tamsulosin (0.4 mg) for 1 week. At the second visit, 47 patients out of the sample of 173 who were still experiencing inconvenient LUTS were randomized into two groups. The first group received a therapy with tamsulosin and fesoterodine combination (group 1, n = 24) while the second continued the therapy with the single administration of tamsulosin (group 2, n = 23) for an additional 4-week period.
  
  
  RESULTS
  There was no statistically significant difference in age, prostate volume, Q, and postvoid residual urine between the two groups. A statistical significance appeared in the combination group regarding the storage and the total IPSS values among the second and third visits (10.5 ± 1.4 to 8.5 ± 1.3 and 16.1 ± 1.8 to 13.7 ± 1.5 respectively).
  
  
  CONCLUSIONS
  Regarding bothersome LUTS and storage symptoms, fesoterodine ER and tamsulosin combination was significantly more effective than the single administration of tamsulosin.
authors.affiliation: Department of Urology, National Institute of Rehabilitation, Athens, Greece.
authors.forename: Charalampos
authors.initials: C
authors.lastname: Konstantinidis
authors.forename: Michael
authors.initials: M
authors.lastname: Samarinas
authors.forename: Sotirios
authors.initials: S
authors.lastname: Andreadakis
authors.forename: Stylianos
authors.initials: S
authors.lastname: Xanthis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Skriapas
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage; D000368:Aged; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D018680:Cholinergic Antagonists / Q000008:administration & dosage; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000503:physiopathology*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D014551:Urinary Tract / Q000187:drug effects / Q000503:physiopathology*
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D003692:Delayed-Action Preparations; D013449:Sulfonamides; C526675:fesoterodine; D000077409:Tamsulosin